C. R. Bard v. AngioDynamics: Defendant Wins on Merits After 8-Year Port Patent Battle
C. R. Bard and Bard Peripheral Vascular asserted three patents covering power injectable subcutaneous access ports against AngioDynamics in the Delaware District Court. After more than 3,000 days of litigation, the court granted AngioDynamics's motion for judgment as a matter of law, ending the case in the defendant's favour.
Eight-Year Port Patent War Ends in JMOL Victory for AngioDynamics
On 10 March 2015, C. R. Bard, Inc. and its subsidiary Bard Peripheral Vascular, Inc. filed suit in the Delaware District Court against AngioDynamics, Inc. (Case No. 1:15-cv-00218), asserting infringement of three patents: US8545460B2, US8805478B2, and US8475417B2. The patents collectively cover assemblies for identifying power injectable access ports, infusion apparatuses and related methods, and methods of performing power injection procedures involving subcutaneously implanted access ports used to deliver contrast media.
The case closed on 1 June 2023 — 3,005 days after filing. The recorded Basis of Termination is 'Judgment on the merits for Defendant.' The docket verdict states that, pursuant to an order granting AngioDynamics's motion for judgment as a matter of law entered on the same date, judgment was ordered in favour of AngioDynamics and against both Bard entities, and the action was dismissed. A JMOL is a merits ruling; it means the court found that no reasonable jury could have found for the plaintiffs on the evidence presented.
The duration of this litigation — more than eight years — is notable even by the standards of complex patent cases in Delaware. What drove the timeline, whether related inter partes review proceedings or appeals contributed to the delay, and the specific evidentiary grounds on which the JMOL was granted are not disclosed in the available record. The defendant's JMOL victory extinguishes the asserted claims in this action, though the patents themselves remain in force unless separately invalidated.
See Complete Case & Patent Analysis →Filing to Judgment on the merits for Defendant in 3005 days
3,005 days — among the longest patent trials in D. Del. before resolution
US8545460B2, US8805478B2 & US8475417B2 — Power Injectable Access Port Technology
Any manufacturer, distributor, or healthcare system procuring power injectable subcutaneous access ports should assess freedom-to-operate against the surviving Bard/BD port patent family. The JMOL in this case does not narrow or invalidate the patent claims — it only resolves this specific infringement action against AngioDynamics. New product designs, firmware-based identification features, or modified clinical protocols in this space may still read on one or more of the three asserted patents.
Official order — verbatim text
The verdict records a JMOL entered by the court pursuant to its own order on the same date, with judgment ordered in favour of AngioDynamics on the infringement action brought by both Bard entities. A JMOL under FRCP 50 constitutes a ruling that the evidence at trial was legally insufficient to support a plaintiff's verdict. The specific claim elements on which the court found the evidence deficient are not stated in the available public record.
Judgment for AngioDynamics: what the JMOL ruling means for both parties
Judgment as a matter of law: a merits ruling, not a procedural exit
A judgment as a matter of law (JMOL) under Federal Rule of Civil Procedure 50 is granted when a court determines that no reasonable jury could find for the non-moving party on the evidence adduced at trial. Unlike a settlement or voluntary dismissal, a JMOL is a substantive adjudication on the merits. Here, the court entered judgment for AngioDynamics, meaning Bard's infringement case was found legally insufficient to sustain a verdict.
Merits adjudicationBard loses the infringement action — patents survive but claims fail here
The JMOL disposes of Bard's infringement claims against AngioDynamics in this action. The three asserted patents — US8545460B2, US8805478B2, and US8475417B2 — are not invalidated by this ruling; they remain in force. Bard may still assert them against other parties. However, the merits finding for AngioDynamics is a significant evidentiary setback, and the specific grounds for the ruling are not disclosed in the available record.
Infringement claims dismissedAngioDynamics cleared — JMOL provides strong litigation closure
AngioDynamics secured a judgment on the merits, not merely a procedural dismissal. This provides stronger res judicata protection than a settlement or voluntary dismissal would. AngioDynamics's power injectable port products are cleared of the specific infringement allegations brought by Bard in this action. Whether AngioDynamics pursued any invalidity counterclaims to final judgment is not stated in the available record.
Full merits vindicationCompetitive dynamics in the power injectable port market remain open
Bard (now part of BD) holds patents that remain enforceable despite this loss. Competitors in the implantable port and vascular access space should note that the JMOL does not invalidate the asserted patents — it only forecloses this infringement action against AngioDynamics. Other manufacturers whose products may read on US8545460B2, US8805478B2, or US8475417B2 remain exposed. A freedom-to-operate analysis against the surviving Bard portfolio is warranted.
Portfolio enforcement risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | C. R. Bard, Inc. | Company | Medical device manufacturer — holder of US8545460B2, US8805478B2, and US8475417B2Search in Eureka ↗ |
| Co-Plaintiff | Bard Peripheral Vascular, Inc. | Company | Search in Eureka ↗ |
| Defendant | AngioDynamics, Inc. | Company | Medical device company specialising in vascular access and oncology productsSearch in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dylan J. Raife | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | John G. Day | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lauren N. Martin | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew A. Traupman | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nicole M. Smith | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Rose S. Lee | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Steven C. Cherny | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Tiffany Geyer Lydon | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Vincent J. Belusko | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing C. R. Bard, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Bindu Ann George Palapura | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Brandon Ryan Harper | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Carson Bartlett | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Catherine N. Taylor | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher A. Hughes | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Danielle V. Tully | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | David A. Cole | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | David Ellis Moore | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Deanna Thompson | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Jaclyn A. Hall | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | John Augelli | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | John T. Moehringer | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Joseph Facciponti | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Maegan A. Fuller | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael B. Powell | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael J. Sebba | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael W. Glenn | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Regina M. Lutz | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert M. Pollaro | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephanie E. O'Byrne | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant counsel | Tyler D. Ricker | Attorney | Counsel for AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant law firm | DLA Piper LLP (US) | Law Firm | Representing AngioDynamics, Inc.Search in Eureka ↗ |
| Defendant law firm | Potter, Anderson & Corroon LLP | Law Firm | Representing AngioDynamics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the power injectable vascular access port space
Forward-looking patent and innovation intelligence derived from the Bard v. AngioDynamics port patent dispute and the broader implantable access port technology landscape.
Bard/BD's power injectable port patent family: scope and activity
C. R. Bard (now Becton Dickinson) has built a layered portfolio covering port identification, infusion apparatus design, and injection methods. Monitoring continuation and divisional filings from the US8545460, US8805478, and US8475417 families reveals how BD is extending claim coverage into newer port designs, wireless identification features, and imaging-compatible materials — signalling continued enforcement intent.
BD/Bard port portfolioFiling trends in implantable port identification and contrast injection
Patent filings in the power injectable port space have expanded beyond mechanical identification features to include RFID tagging, CT-visible markers, and electronic port verification systems. Tracking IPC class A61M39 and related subclasses over the past five years reveals which assignees — including new entrants — are most active in next-generation port identification technology that may intersect with the surviving Bard claim scope.
Port ID filing trendsAngioDynamics's patent strategy in vascular access post-JMOL
AngioDynamics markets its own implantable port line and has its own patent activity in vascular access and oncology. Examining AngioDynamics's filed and granted patents in the port and catheter space post-2015 reveals whether the company has built defensive IP around the product features challenged by Bard — and whether any cross-licensing opportunity exists with BD going forward.
AngioDynamics IP positionAdjacent innovation gaps: smart port verification and clinical workflow IP
The Bard patents focus on physical and visual identification assemblies. White space exists in digitally integrated port verification — including app-based identification, intraoperative imaging confirmation, and electronic medical record linkage for port type documentation. These adjacent claim spaces are less densely filed and represent R&D and IP filing opportunities for device innovators seeking differentiation without conflicting with surviving Bard claims.
Smart port white spaceSimilar patent cases: power injectable port & vascular access IP in D. Del.
Explore comparable medical device infringement actions in the Delaware District Court involving implantable port, vascular access, and power injection patents.
What this case signals for the vascular access port IP landscape
An eight-year JMOL defeat for a major medical device patentee carries sector-wide implications for port technology enforcement and FTO strategy.
JMOL outcomes signal evidentiary fragility in complex device patent claims
When a district court grants JMOL for a defendant in a medical device patent case, it signals that the plaintiff's infringement evidence failed to meet the legal sufficiency threshold. Companies enforcing multi-element method and assembly claims — as here — should stress-test claim charts and expert testimony before trial to avoid a similar outcome after years of litigation costs.
Bard's three surviving patents remain enforcement tools despite this loss
US8545460B2, US8805478B2, and US8475417B2 are not invalidated by this ruling. Any company manufacturing or distributing power injectable subcutaneous access ports should treat this JMOL as AngioDynamics-specific. The Bard/BD portfolio in this space continues to present a live FTO risk for competitors and new market entrants.
C. v AngioDynamics — key questions answered
The Delaware District Court entered judgment on the merits in favour of AngioDynamics. The court granted AngioDynamics's motion for judgment as a matter of law (JMOL) and dismissed the action brought by C. R. Bard, Inc. and Bard Peripheral Vascular, Inc. The Basis of Termination is recorded as 'Judgment on the merits for Defendant.'
Bard asserted three patents: US8545460B2 (assemblies for identifying a power injectable access port), US8805478B2 (infusion apparatuses and related methods), and US8475417B2 (methods of performing a power injection procedure including identifying features of a subcutaneously implanted access port for delivery of contrast media).
No. A JMOL under FRCP 50 is a ruling that the plaintiff's evidence was legally insufficient to sustain a finding of infringement. It does not invalidate the asserted patents. US8545460B2, US8805478B2, and US8475417B2 remain in force and may be asserted against other parties unless separately challenged and invalidated.
The case was filed on 10 March 2015 and closed on 1 June 2023 — a duration of 3,005 days. The specific reasons for this extended timeline are not disclosed in the available public record. Complex medical device patent cases in the District of Delaware involving multiple patents and method claims frequently involve protracted claim construction proceedings, inter partes review challenges, and pre-trial motions that can extend litigation significantly.
The JMOL is specific to the infringement action against AngioDynamics and does not limit Bard's (now BD's) ability to assert the three patents against other parties. Manufacturers of power injectable subcutaneous access ports should conduct freedom-to-operate analyses against US8545460B2, US8805478B2, and US8475417B2 to assess their own exposure, particularly for products that incorporate identification assemblies or power injection method steps covered by these claims.
PatSnap Eureka searches patents and litigation data to answer instantly.